Active	Status	Sponsor type	Region	Phase	Filter
14 Active 20 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Skoloudik, David
NCT06036368: Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor	Completed	N/A	23	RoW	Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)	Stimvia s.r.o.	Parkinson's Disease, Essential Tremor	03/24	06/24
NCT06570421: 24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor	Recruiting	N/A	20	RoW	Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®), URIS	Stimvia s.r.o.	Parkinson Disease, Essential Tremor	07/26	12/26
Prochazka, Vit
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients	Active, not recruiting	2	168	Europe, RoW	MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab	Miltenyi Biomedicine GmbH, ICON plc	Diffuse Large B-cell Lymphoma	12/24	07/29
Fudalej, Piotr
No trials found
Zatloukal, Jaromir
No trials found